The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis
Abstract
Toxicity due to treatment causes a negative impact on quality of life in breast cancer survivors. Hot flash symptoms, described as intense sensations of heat, sweating and flushing occur in more than 50 % of breast cancer patients taking tamoxifen. We hypothesized that venlafaxine, a selective-norepinephrine reuptake inhibitor drug, was effective for reducing patient-reported hot flash scores among women treated for breast cancer compared to other non-hormonal treatments. We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. The primary outcome was hot flash score (derived from patient-reported hot flash severity and frequency) in randomized controlled trials. Standardized mean differences (SMD) were calculated for each study due to variation in the outcome measures. Heterogeneity was determined using I (2) statistics, and publication bias was assessed using a contour funnel plot and Egger's tests. Pooled analyses demonstrated that venlafaxine significantly reduced hot flash scores compared to the trial comparators (overall SMD 2.06; 95% confidence interval (CI) [0.40, 3.72]). There was significant heterogeneity among these studies (I (2) = 98.7%, P < 0.001). Asymmetry in the contour funnel plot suggests the presence of publication bias and a trend towards small study effects (Egge…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.118, 119, 120, 121”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [118]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309 · cited 1×
“Any procedures based on predictable generation of allocation sequences, and potentially transparent attempts to conceal allocation, such as assignment envelopes, which were not opaque or not sealed, were considered inadequate [19].”
BackgroundMeta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study
Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A. W. S., Tschannen, B., Altman, D. G., Egger, M., & Juni, P. (2010) · BMJ · doi:10.1136/bmj.c3515 · Cited by 559 · cited 1×
“Heterogeneity was assessed using I(2) statistics, and publication bias was determined using a contour funnel plot and Egger’s tests [27, 28].”
MethodHolmberg, L., & Anderson, H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15493-7 · Cited by 533
Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010) · BMJ · doi:10.1136/bmj.c693 · Cited by 466
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.(118-121) Sleep disturbances may be treated with melatonin.”
BackgroundThe 2023 nonhormone therapy position statement of The North American Menopause Society
(2023) · Menopause · doi:10.1097/gme.0000000000002200 · Cited by 309
Self-citationSerotonin and Norepinephrine Reuptake Inhibitors
Shelton, R. C. (2018) · Handbook of Experimental Pharmacology · doi:10.1007/164_2018_164 · Cited by 171
Metadata
- Authors
- Ramaswami, R., Villarreal, M. D., Pitta, D. M., Carpenter, J. S., Stebbing, J., & Kalesan, B.
- Affiliations
- Imperial College London (GB)
- Columbia University (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Kalesan, Bindu
- Venue
- Breast Cancer Research and Treatment
- Published
- 2015-06-12
- Volume
- 152
- Issue
- 2
- Pages
- 231-237
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W627583589
- Cited by
- 49
- References
- 40
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14549)
- National Institute for Health and Care Research (NIHR-RP-011-053)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- venlafaxine, hot flashes, breast cancer, menopausal symptoms, tamoxifen, selective norepinephrine reuptake inhibitors, non-hormonal therapy, breast cancer survivors, quality of life
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Venlafaxine Hydrochloride, Breast Neoplasms, Female, Humans, Treatment Outcome, Disease Management, Hot Flashes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s10549-015-3465-5
- The paper
- Ramaswami, R., Villarreal, M. D., Pitta, D. M., Carpenter, J. S., Stebbing, J., & Kalesan, B. (2015). Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-015-3465-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.